29 results
PRE 14A
ELVN
Enliven Therapeutics Inc
15 Apr 24
Preliminary proxy
4:05pm
sound judgement, tenure on the board of directors and skills that are complementary to the board of directors, an understanding of Enliven’s business … service on the board throughout his tenure. Dr. Lyssikatos will continue to serve as our Chief Scientific Officer. In accordance with our restated
DEF 14A
ct9gk6
18 May 21
Definitive proxy
4:06pm
10-K
iwv9rcbu
5 Mar 21
Annual report
7:26am
8-K
EX-3.2
hyc9u7
16 Mar 20
Amendments to Articles of Incorporation or Bylaws
4:06pm
424B4
iy4c0pdswxcvvgdqx114
12 Mar 20
Prospectus supplement with pricing info
4:03pm
S-1/A
64yqu2 zti6t7
3 Mar 20
IPO registration (amended)
6:13am
S-1
EX-10.8
ju3 dnclar7y
14 Feb 20
IPO registration
5:05pm
S-1
EX-3.2
qm7s3xgd
14 Feb 20
IPO registration
5:05pm
S-1
EX-10.10
du9giw 2x5nd
14 Feb 20
IPO registration
5:05pm
S-1
6kymqo5 xd4hj0
14 Feb 20
IPO registration
5:05pm
S-1
EX-3.4
l3d0gn z14z8lybpmyw
14 Feb 20
IPO registration
5:05pm
S-1
EX-10.9
biw7yzi
14 Feb 20
IPO registration
5:05pm
DRS/A
EX-3.4
zsvmt clazakwi3ekw
8 Oct 19
Draft registration statement (amended)
12:00am